|
Name |
Anhydrocochlioquinone A
|
Molecular Formula | C30H42O7 | |
IUPAC Name* |
[(2S,3R,4S)-2-[(3R,4aR,6S,12bR)-3-(2-hydroxypropan-2-yl)-6,12b-dimethyl-8,11-dioxo-2,3,4a,5,6,6a-hexahydro-1H-pyrano[3,2-a]xanthen-9-yl]-4-methylhexan-3-yl] acetate
|
|
SMILES |
CC[C@H](C)[C@H]([C@@H](C)C1=CC(=O)C2=C(C1=O)OC3[C@H](C[C@@H]4[C@@](C3=C2)(CC[C@@H](O4)C(C)(C)O)C)C)OC(=O)C
|
|
InChI |
InChI=1S/C30H42O7/c1-9-15(2)26(35-18(5)31)17(4)19-14-22(32)20-13-21-27(37-28(20)25(19)33)16(3)12-24-30(21,8)11-10-23(36-24)29(6,7)34/h13-17,23-24,26-27,34H,9-12H2,1-8H3/t15-,16-,17-,23+,24+,26+,27?,30+/m0/s1
|
|
InChIKey |
CBLRPZZCLBREIA-YYRMTXNWSA-N
|
|
Synonyms |
Anhydrocochlioquinone A; CHEBI:182181; [(2S,3R,4S)-2-[(3R,4aR,6S,12bR)-3-(2-hydroxypropan-2-yl)-6,12b-dimethyl-8,11-dioxo-2,3,4a,5,6,6a-hexahydro-1H-pyrano[3,2-a]xanthen-9-yl]-4-methylhexan-3-yl] acetate
|
|
CAS | NA | |
PubChem CID | 134723194 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 514.6 | ALogp: | 4.3 |
HBD: | 1 | HBA: | 7 |
Rotatable Bonds: | 7 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 99.1 | Aromatic Rings: | 4 |
Heavy Atoms: | 37 | QED Weighted: | 0.39 |
Caco-2 Permeability: | -5.022 | MDCK Permeability: | 0.00002350 |
Pgp-inhibitor: | 0.728 | Pgp-substrate: | 0.993 |
Human Intestinal Absorption (HIA): | 0.39 | 20% Bioavailability (F20%): | 0.933 |
30% Bioavailability (F30%): | 0.992 |
Blood-Brain-Barrier Penetration (BBB): | 0.769 | Plasma Protein Binding (PPB): | 97.74% |
Volume Distribution (VD): | 1.704 | Fu: | 3.62% |
CYP1A2-inhibitor: | 0.054 | CYP1A2-substrate: | 0.084 |
CYP2C19-inhibitor: | 0.033 | CYP2C19-substrate: | 0.502 |
CYP2C9-inhibitor: | 0.22 | CYP2C9-substrate: | 0.327 |
CYP2D6-inhibitor: | 0.053 | CYP2D6-substrate: | 0.073 |
CYP3A4-inhibitor: | 0.765 | CYP3A4-substrate: | 0.792 |
Clearance (CL): | 2.439 | Half-life (T1/2): | 0.631 |
hERG Blockers: | 0.003 | Human Hepatotoxicity (H-HT): | 0.048 |
Drug-inuced Liver Injury (DILI): | 0.395 | AMES Toxicity: | 0.013 |
Rat Oral Acute Toxicity: | 0.978 | Maximum Recommended Daily Dose: | 0.975 |
Skin Sensitization: | 0.731 | Carcinogencity: | 0.051 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.38 |
Respiratory Toxicity: | 0.94 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004573 | 0.633 | D02IQY | 0.232 | ||||
ENC000943 | 0.613 | D09WYX | 0.230 | ||||
ENC005797 | 0.532 | D0F7NQ | 0.224 | ||||
ENC004571 | 0.522 | D0K7LU | 0.223 | ||||
ENC004251 | 0.481 | D08BDT | 0.223 | ||||
ENC001862 | 0.471 | D0W2EK | 0.222 | ||||
ENC004572 | 0.467 | D03ZZK | 0.222 | ||||
ENC002182 | 0.467 | D04SFH | 0.219 | ||||
ENC002674 | 0.455 | D0I2SD | 0.219 | ||||
ENC004570 | 0.454 | D0H0ND | 0.215 |